Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Suicide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    362 result(s) found for: Suicide. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-021024-10 Sponsor Protocol Number: 019-2010 Start Date*: 2011-04-19
    Sponsor Name:Organisation name was not entered
    Full Title: Anit-Inflammatory treatment to decrease suicidality in patients with a recent suicide attempt and a depressive disorder
    Medical condition: Patients with a recent suicide attempt and a depressive disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011409-17 Sponsor Protocol Number: LAST-RD - FARM77Z3BL Start Date*: 2009-10-01
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
    Full Title: Randomized evaluation of the effectiveness of lithium in subjects with treatment-resistant depression and suicide risk. An independent, pragmatic, multicentre, parallel-group, superiority trial.
    Medical condition: Treatment-resistant depression and suicide risk.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012397 Depression suicidal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001518-40 Sponsor Protocol Number: 848040001 Start Date*: 2020-01-31
    Sponsor Name:VU Medical Center
    Full Title: Netherlands study of Optimal, PERsonalized Antidepressant use (OPERA-DISCONTINUATION)
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004443-11 Sponsor Protocol Number: A5361022 Start Date*: 2009-02-04
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A 52-WEEK OPEN-LABEL SAFETY STUDY OF PD 0332334 IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003992-23 Sponsor Protocol Number: 54135419SUI3002 Start Date*: 2017-07-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) CZ (Completed) AT (Completed) LT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004422-42 Sponsor Protocol Number: ESKETINSUI2002 Start Date*: 2017-10-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Restarted) BE (Completed) PL (Completed) IT (Completed) BG (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003990-17 Sponsor Protocol Number: 54135419SUI3001 Start Date*: 2017-05-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) HU (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-001522-30 Sponsor Protocol Number: RIMOFATSCI-2 Start Date*: 2022-10-03
    Sponsor Name:Fundación Hospital Nacional de Parapléjicos
    Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries
    Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003816-38 Sponsor Protocol Number: PHRC-N/2017-FJ-01 Start Date*: 2020-11-09
    Sponsor Name:CHU DE NIMES
    Full Title: Add-on buprenorphine at analgesic doses for the treatment of severe suicidal ideas during a major depressive episode
    Medical condition: Treatment of severe suicidal ideas in patients suffers from a current major depressive episode
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10083288 Clinical depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002067-14 Sponsor Protocol Number: 3151A6-2001 Start Date*: 2015-04-03
    Sponsor Name:Wyeth Research
    Full Title: 6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent O...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004899-35 Sponsor Protocol Number: 331-201-00191 Start Date*: 2024-06-13
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Open Label Trial to Evaluate the Long-term Safety and Tolerability of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectru...
    Medical condition: Irritability Associated With Autism Spectrum Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001599-46 Sponsor Protocol Number: F1J-MC-HMGI Start Date*: 2017-05-09
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000685-29 Sponsor Protocol Number: B4Z-KL-LYEC Start Date*: 2021-08-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000064-28 Sponsor Protocol Number: RAP-MD-33 Start Date*: 2018-11-28
    Sponsor Name:Allergan Ltd.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004006-81 Sponsor Protocol Number: LTE5376 Start Date*: 2006-06-01
    Sponsor Name:sanofi-aventis recherche&developpement
    Full Title: A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of d...
    Medical condition: patients with major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-002425-30 Sponsor Protocol Number: 0171 Start Date*: 2020-03-17
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects...
    Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) ES (Prematurely Ended) PL (Completed) EE (Completed) FR (Completed) PT (Prematurely Ended) AT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004745-70 Sponsor Protocol Number: 55438 Start Date*: 2018-11-06
    Sponsor Name:Academic Medical Center (AMC)
    Full Title: Efficacy of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial Amsterdam, KETA)
    Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000970-31 Sponsor Protocol Number: TUD-ASLith-057 Start Date*: 2013-11-27
    Sponsor Name:Technische Universität Dresden
    Full Title: Randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) for acute suicidal ideation and behaviour in patients with suicidal major depressive episode
    Medical condition: Diagnosis of a major depressive episode; inpatient at screening visit; suicidal ideation/behaviour present defined by a clinical rating of ≥ 8 on the Sheehan Suicidality Tracking Scale (S-STS) at...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002905-24 Sponsor Protocol Number: 74304 Start Date*: 2021-07-07
    Sponsor Name:University Medical Center Groningen
    Full Title: Efficacy and feasibility of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial for Acute suicidalty, KETA)
    Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000203-16 Sponsor Protocol Number: SOMCT02 Start Date*: 2018-06-18
    Sponsor Name:SOM Biotech
    Full Title: Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements.
    Medical condition: Chorea movements associated with Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10020469 Huntington's chorea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 00:28:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA